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Association of Myocardial Deformation With
Mortality Independent of Myocardial Ischemia
and Left Ventricular Hypertrophy
Tony Stanton, MB, CHB, PHD,* Charlotte Bjork Ingul, MD,† James L. Hare, MBBS,*
Rodel Leano, BS,* Thomas H. Marwick, MD, PHD*
Brisbane, Australia; and Trondheim, Norway
O B J E C T I V E S The aim of this study was to investigate the relative contributions of left ventricular
hypertrophy (LVH) and myocardial ischemia to the association between abnormal myocardial deforma-
tion during dobutamine stress echocardiography (DSE) and mortality.
B A C KG ROUND Both left ventricular hypertrophy (LVH) and myocardial ischemia are known to
convey a signiﬁcant adverse prognostic impact. In addition, myocardial deformation is an independent
predictor of outcome in patients undergoing DSE. The mechanism of this association, however, is
undeﬁned.
METHOD S We studied 223 consecutive individuals with normal resting LV function undergoing
DSE. The LV mass was indexed to height (g/m2.7) (LVMI), and LVH was designated as LVMI 51 g/m2.7.
Myocardial ischemia was deﬁned on the basis of new, inducible wall motion abnormalities. Customized
software was used to measure global strain rate (SRs), which was averaged in 18 myocardial segments
at peak stress. Individuals were followed for all-cause mortality over a mean of 5.4  1.4 years.
R E S U L T S Left ventricular hypertrophy was identiﬁed in 83 individuals (37%), and 63 (28%) had
ischemia documented at DSE. In a Cox proportional hazards model, the strongest predictor of all-cause
mortality for the total population was SRs (hazard ratio: 2.16, 95% conﬁdence interval: 1.63 to 2.87, p 
0.01). Both LVH (p  0.01) and ischemia (p  0.05) had a signiﬁcant adverse prognostic impact.
Individuals with both LVH and ischemia had the worst outcome (p  0.02) in comparison with the rest
of the population. Among LV geometric patterns, concentric LVH had the worst outcome (p  0.01).
However, SRs was the strongest predictor of mortality in both LVH and ischemia. In a model reﬂecting
clinical practice, SRs provided a signiﬁcant increment in model power over baseline and variables
identiﬁed at DSE.
CONC L U S I O N S The SRs is a powerful, independent predictor of all-cause mortality in individuals
undergoing DSE and provides incremental information over baseline clinical and echocardiographic
variables. Whereas SRs is inﬂuenced by both LVH and myocardial ischemia, both independently and
additively, its predictive power for mortality is independent of both. (J Am Coll Cardiol Img 2009;2:
793–801) © 2009 by the American College of Cardiology Foundation
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794lthough patients presenting with cardiac
symptoms with normal left ventricular (LV)
systolic function generally have a favorable
outcome, echocardiographic assessment
s able to identify subgroups of varying risk. Left
entricular hypertrophy (LVH) (1) and LV filling
bnormalities (2) are associated with increased mor-
ality. The results of dobutamine stress echocardi-
graphy (DSE) have been linked to both cardiac
nd overall outcome (3). The presence of LVH
ignificantly adds to the prognostic information
rovided by DSE (4).
Deformation to applied stress is related to myocar-
ial properties and might be due to myocardial scar
5), ischemia (6), and hypertrophy (7). Interstitial
brosis is another important mechanism of myocar-
ial disease—although linked to hypertrophy, its eti-
ology and progression seem to be indepen-
dent of myocyte hypertrophy (8). In this
study of patients with normal resting LV
function, we sought to link deformation and
outcome independent of the effects of LVH,
ischemia, and infarction.
M E T H O D S
Study population. Between 1998 and 2000,
our laboratory performed 520 consecutive
DSE studies in patients with normal resting
LV function. Patients with 1 DSE had
their first DSE included (n  17). Other
exclusions were due to poor image quality
and acquisition problems (n 68) or inabil-
ity to accurately estimate left ventricular
mass index (LVMI) (n  156). Outcome
data was not available for 56 patients.
herefore, the final study population comprised 223
atients (Table 1).
esting and stress echocardiography. Beta-adreno-
eptor and calcium channel antagonists were with-
rawn on the day before the test. Cine loops from
apical views (4-chamber, 2-chamber, and apical
ong-axis) were recorded with gray-scale harmonic
nd tissue Doppler modes at rest and each stage of
tress with a standard DSE protocol. The LV was
ivided into 16 segments and coded as: 1 normal,
A  hypokinetic, 2B  severely hypokinetic, 3 
kinetic, or 4  dyskinetic. Ischemia was identified
y an experienced reader due to the presence of
nducible wall motion abnormalities.
alculation of LV mass. M-mode LV mass was cal-
ulated with the formula: LV mass  0.8 
r
s
re
ain
rain1.04[([LV internal dimension  septal wall thick- tess  posterior wall thickness]3  LV internal
imension3)]}  0.6 g. Left ventricular mass was
ndexed to height2.7, and LVH was defined as 51
/m2.7 for both sexes (9). Relative wall thickness
RWT) was calculated with the formula: (2 · posterior
all thickness)/LV internal dimension. The RWT
s abnormal if it is 0.42. The mean LVMI for
he total population was 48  14 g/m2.7, mean
WT was 0.46  0.11, and ejection fraction was
3  8%.
nalysis of myocardial deformation. Myocardial de-
ormation was measured with automated software
Matlab, MathWorks Inc., Natick, Massachusetts)
10). Longitudinal strain rate (SRs) was calculated
rom the velocity gradient along the ultrasound
eam and strain as the temporal integral of strain
ate. Measurements were made by 1 experienced
bserver blinded to clinical data. The coefficient of
ariation was 16% (intraobserver) and 17% (inter-
bserver) (10). The SRs was defined as the most
egative SRs value during the ejection period (Fig.
). End-systolic strain (SEs) was defined as the
train value at aortic valve closure. The SRs and SEs
ere calculated at peak stress and then averaged in
8 myocardial segments to provide global values.
ollow-up. The primary end point of the study was
ll-cause mortality. The follow-up period was
eemed to have commenced on the day of DSE.
tatistical analysis. Student t test was used to com-
are continuous variables, and the chi-square test
as used to compare categorical variables. Univar-
ate analysis was performed to establish the rela-
ionship between baseline clinical and echocardio-
raphic variables and all-cause mortality. Survival
fter DSE was expressed with Kaplan-Meier anal-
sis and log-rank tested for significance both overall
nd between strata. The independence and incre-
ental value of SRs over baseline and DSE-
btained variables was assessed in a series of Cox
odels. Variables known at baseline, then variables
btained at DSE, and finally SRs were entered into
he model in a series of steps. Model chi-square was
hen compared at each step. All continuous vari-
bles were assessed per unit SD to facilitate com-
arisons. Significance was measured as 0.05.
E S U L T S
linical characteristics. The clinical characteristics of
he 223 study patients were not significantly differ-
nt from the 297 patients excluded, with the excep-
ion of a significantly higher prevalence of hyper-B B R E V I A T I O N S
N D A C R O N YM S
SE dobutamine stress
chocardiography
V left ventricle/ventricula
VH left ventricular
ypertrophy
VMI left ventricular mass
ndex
WT relative wall thicknes
BP systolic blood pressu
Es global end-systolic str
t peak stress
Rs global peak systolic st
ate at peak stress
) presence ofension in the included group (Table 1).
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795VH. Left ventricular hypertrophy was identified in
3 individuals (37%). These individuals were sig-
ificantly older (62  12 years vs. 58  12 years,
 0.01), had higher body mass index (29.6  6.0
g/m2 vs. 26.7  4.9 kg/m2, p  0.01), more
iabetes (31% vs. 16%, p  0.05) and hypertension
66% vs. 46%, p  0.01), and accordingly higher
esting systolic blood pressure (SBP) levels (150 
4 mm Hg vs. 139  23 mm Hg, p  0.01). There
ere no significant differences in the use of medi-
ations between those with and without LVH.
A   Peak SRs in patient without LVH 
B  Peak SRs in patient with combina
SRs
0 0.05 0.1 0.15 0.2
avo
1
0
-1
0 0.05
avo
SRs
0.1 0.15
2
0
-2
0
Figure 1. Examples of SRs Curves
Examples of peak systolic strain rate (SRs) curves in (A) patient with
Table 1. Population Demographic Data
Age (yrs)
Weight (kg)
Height (m)
Body mass index (kg/m2)
Body surface area (m2)
Male sex
Diabetes mellitus (fasting glucose 7.0 mmol/l)
Hypertension (BP 140/90 mm Hg)
Hypercholesterolemia (total cholesterol 4.0 mmol/l)
Current or previous angina
Smoking
Current use of beta-blockers
Current use of calcium channel blockers
Current use of nitrates
Data are expressed as mean  SD or n (%). *p  0.05 compared with “Include
BP  blood pressure.(B) patient with LVH and ischemia at peak stress. avc  aortic valve cloyocardial ischemia. The DSE evidence of myocar-
ial ischemia was identified in 63 patients (28%).
hese individuals were significantly older (64  10
ears vs. 58  12 years, p  0.01) and had lower
esting heart rates (70  13 beats/min vs. 78  14
eats/min, p  0.01), possibly because there was
igher use of routine beta-blockade in this group
62% vs. 21%, p  0.01) due to pre-existing angina
63% vs. 33%, p  0.01).
The average peak SRs was 2.48  0.62 s1,
ith SEs 12.1  4.9%. The SRs was reduced in
schemia at peak stress 
 of LVH and ischemia at peak stress
5 0.3 0.35 0.4 0.45
0.25 0.3 0.35 0.4
left ventricular hypertrophy (LVH) or ischemia at peak stress and
Included (n  223) Excluded (n  297)
59.5  11.8 60.2  12.8
78.2  16.9 78.3  22.0
1.68  0.10 1.69  0.11
27.7  5.5 27.7  5.8
1.87  0.2 1.90  0.3
122 (54.5) 177 (59.6)
49 (21.9) 43 (14.5)
121 (54.0) 126 (42.4)*
96 (42.9) 126 (42.4)
93 (41.5) 128 (43.1)
46 (20.5) 69 (23.2)
73 (32.6) 107 (36.0)
62 (27.7) 72 (24.2)
55 (24.5) 79 (26.6)
oup.or i
tion
0.2
avc
.2
outd” grsure; avo  aortic valve opening.
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796he 63 patients with ischemia (1.97  0.50 vs.
2.68  0.55, p  0.01) and the 83 patients with
VH (2.31  0.69 vs. 2.58  0.55; p  0.01).
ikewise, global SEs was reduced in both ischemia
9.1  4.5 vs. 13.3  4.7; p  0.01) and LVH
11.1  5.0 vs. 12.8  4.7; p  0.05).
ollow-up. The mean follow-up time was 5.4  1.4
ears, and over the course of follow up, 33 individ-
als died (14.8%). The significant univariate pre-
ictors of mortality from data known before DSE
ere: LVH (hazard ratio [HR]: 2.82, 95% confi-
ence interval [CI]: 1.40 to 5.68); diabetes (HR:
.32, 95% CI: 1.14 to 4.73); resting heart rate (HR:
.44, 95% CI: 1.06 to 1.94); and RWT (HR: 1.42,
5% CI: 1.11 to 1.83). Significant univariate pre-
ictors of mortality from data obtained from DSE
ere: SRs (HR: 2.22, 95% CI: 1.66 to 2.96);
schemia (HR: 2.07, 95% CI: 1.03 to 4.14); SEs
HR: 1.52, 95% CI: 1.11 to 2.09); peak heart rate
HR: 0.97, 95% CI: 0.95 to 1.00), and peak SBP
HR: 0.67, 95% CI: 0.47 to 2.09). Left ventricular
ypertrophy was the strongest baseline clinical pre-
ictor of outcome, and SRs was the strongest
redictor at peak stress.
OTAL POPULATION. For the total population, the
aseline LVH (HR: 2.80, 95% CI: 1.39 to 5.63,
 0.01) and resting heart rate (HR: 1.45, 95% CI:
.06 to 1.99, p  0.05) were significant indepen-
ent predictors. However, after the addition of
ariables obtained from DSE, only SRs (HR: 2.16,
5% CI: 1.63 to 2.87, p  0.01) and peak SBP
HR: 0.69, 95% CI: 0.48 to 0.99, p  0.05) were
ignificant.
YOCARDIAL ISCHEMIA. Ischemia was associated
ith reduced survival (Fig. 2). The independent
redictors of all-cause mortality in those without
schemia at DSE were LVH (HR: 3.64, 95% CI:
.42 to 9.33, p  0.01) and resting heart rate (HR:
.91, 95% CI: 1.30 to 2.82, p 0.01). The addition
f variables obtained from DSE to the model
emonstrated that strain rate was the strongest
redictor (HR: 1.74, 95% CI: 1.16 to 2.63, p 
.01), although resting heart rate was also retained
HR: 1.65, 95% CI: 1.12 to 2.45, p  0.05). In
hose with ischemia, none of the clinical variables
ere significant predictors, but SRs was a signifi-
ant predictor (HR: 3.09, 95% CI: 1.66 to 5.74,
 0.01).
VH. The effect of LVH on survival is shown in
igure 2. Only diabetes (HR: 3.67, 95% CI: 2.10 toCu
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Figure 2. Kaplan-Meier Curves Depicting Event-Free Survival for
Ischemia, LVH, and RWT
Kaplan-Meier curves depicting event-free survival in (A) individuals with
and without myocardial ischemia at dobutamine stress echocardiogra-
phy, (B) individuals with and without left ventricular hypertrophy (LVH),
and (C) individuals with normal and raised relative wall thickness (RWT).
The n values along the x-axis show individuals at risk for each follow-up7.78, p 0.01) was a significant predictor in those
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797ithout LVH from baseline variables. The addition
f variables obtained from DSE to the model
etained diabetes (HR: 7.64, 95% CI: 2.10 to 27.78,
 0.01) but also added SRs (HR: 3.66, 95% CI:
.12 to 6.30, p  0.01) and peak SBP (HR: 0.37,
5% CI: 0.21 to 0.66, p  0.01). In those with
VH the only significant predictor was SRs (HR:
.61, 95% CI: 1.08 to 2.39, p  0.01).
VH AND ISCHEMIA. The group was partitioned
nto 4 groups on the basis of the presence or absence
f LVH and the presence or absence of ischemia at
SE (Table 2). Log-rank comparison between
roups showed significantly better survival in pa-
ients with neither LVH nor ischemia (p  0.05)
ompared with each of the other 3 groups (Fig. 3).
The SRs was the only variable found to be a
ignificant, independent predictor of all-cause mor-
ality in each of these 4 groups. It was also the
trongest predictor in the overall group and in 3 of
he 4 subgroups (Table 3). When the presence/
bsence of ischemia and LVH were combined,
here was a clear stepwise gradation in SRs and SEs
rom the group without LVH or ischemia toward
he group with both (Fig. 3).
V geometry and RWT. The combination of LVMI
Table 2. Comparison of Patients With/Without Ischemia and LV
LVH ()
Ischemia ()
(n  106)
Age (yrs) 56.4 11.9
Weight (kg) 75.6 15.8
Height (m) 1.69 0.09
Body mass index (kg/m2) 26.4 5.1
Body surface area (m2) 1.86 0.21
Male sex 50.9
Diabetes mellitus
(fasting glucose 7.0 mmol/l)
11.3
Hypertension (BP 140/90 mm Hg) 44.3
Hypercholesterolemia
(total cholesterol 4.0 mmol/l)
35.8
Current or previous angina 36.8
Smoking 24.5
Beta-blocker therapy 18.9
Calcium channel blockers 21.7
Nitrate therapy 17
Strain SEs (%) 13.66 4.21
Strain rate SRs (s1) 2.75 0.46
All data are expressed as mean  SD; SRs, resting heart rate, peak SBP all analy
testing was used for between-groups analysis of variance (ANOVA). Chi square te
between 4 groups (ANOVA); †p  0.05 overall between groups 1 and 4; ‡p  0.
groups 2 and 3; ¶p  0.05 between groups 2 and 4.
BP  blood pressure; LVH  left ventricular hypertrophy; SEs  global end-sys
strain rate at peak stress.nd RWT allows for partition into 4 categories of pV geometry: normal (LVMI 51 g/m2.7, RWT
0.42, n  76 [34.1%]), concentric remodeling
LVMI 51 g/m2.7, RWT 0.42, n  64
28.7%]), eccentric hypertrophy (LVMI 51
/m2.7, RWT 0.42, n  23 [10.3%]), and con-
entric hypertrophy (LVMI 51 g/m2.7, RWT
0.42, n  60 [26.9%]). The only significant
ifference in outcome was between the normal geom-
try and concentric LVH groups (p  0.01) (Fig. 3).
redictors of outcome for each geometric group are
hown in Table 4. The SRs was the strongest predic-
or in every group apart from eccentric LVH. This is
ost likely due to the inability of the test to establish
redictors in such a small sample (n  23).
Mean RWT for the total population was 0.46 
.11. Those with abnormal RWT (n  124) had
orse survival compared with normal RWT (n 99;
 0.05) (Fig. 2). In contrast to LVH, however,
here was no significant difference between the groups
or SRs (normal RWT 2.54  0.58 s1 vs. abnormal
WT 2.44  0.65 s1, p  0.05). Diabetes (HR:
.90, 95% CI: 1.28 to 6.56, p  0.01) predicted
utcome in those with abnormal RWT. However,
fter entering variables obtained at DSE, SRs (HR:
.31, 95% CI: 1.66 to 3.23, p  0.01) was the only
LVH ()
Ischemia ()
(n  54)
LVH ()
Ischemia ()
(n  34)
LVH ()
Ischemia ()
(n  29)
60.0 12.3 62.3 10.3 66.8 8.3*†
81.8 19.6 73.4 14.1 79.6 17.8
1.66 0.11 1.70 0.09 1.65 0.10*
29.7 6.3‡ 27.4 4.2 29.2 5.4*
1.89 0.24 1.90 0.19 1.86 0.23
53.7 64.7 55.2
33.3‡ 29.4§ 27.6*
64.8‡ 52.9 69*†
37.0 34.7§ 51.7*
27.8 70.6§ 48.3*
14.8 17.6 17.2
27.8 70.6§ 44.8*†
33.3 29.4 34.5
14.8 47.1§ 41.4*†¶
12.73 4.86 9.94 4.95§ 8.07 3.73*†¶
2.56 0.67 2.08 0.51§ 1.85 0.47*†¶
er unit SD. Data are expressed as % unless otherwise stated. Scheffe post hoc
was carried out for differences between categorical variables. *p 0.05 overall
tween groups 1 and 2; §p  0.05 between groups 1 and 3; p  0.05 between
strain at peak stress; SBP  systolic blood pressure; SRs  global peak systolicH
zed p
sting
05 be
tolicredictive factor (Table 4). In those with normal
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798Follow-up (Years)
Log Rank Chi Square = 12.53
p < 0.01
0 2 4 6 8
n=223 n=213 n=203 n=191 n=190
LVH (–) Ischemia (+)
LVH (–) Ischemia (–)
LVH (+) Ischemia (–)
LVH (+) Ischemia (+)
Follow-up (Years)
Log Rank Chi Square = 12.76
p < 0.01
0 2 4 6 8
n=223 n=213 n=203 n=191 n=190
Eccentric LVH
Normal Geometry
Concentric Remodeling
Concentric LVH
Kaplan-Meier Curves Depicting Event-Free Survival for
s on the Basis of Presence/Absence of Ischemia and LVH and
try
ier curve depicting event-free survival for individuals (A) grouped
sence ()/absence () of left ventricular hypertrophy (LVH) and
nd (B) according to their left ventricular geometry. The n values
x-axis show individuals at risk for each follow-up period.
Table 3. Predictors of All-Cause Mortality in Those With/Withou
Baseline
HR 95% CI p
LVH ()
Ischemia ()
(n  106)
Resting
heart rate
2.18 1.30–3.65
LVH ()
Ischemia ()
(n  34)
LVH ()
Ischemia ()
(n  54)
LVH ()
Ischemia ()
(n  29)
SRs, resting heart rate, peak SBP all analyzed per unit SD.
CI  conﬁdence interval; DSE  dobutamine stress echo; HR  hazard ratio; () WT, none of the baseline or subsequent DSE
ariables was predictive of mortality.
ndependent and incremental value of SRs over base-
ine and DSE-obtained variables. For the population
s a whole, the model was fitted to reflect the
ariables taken into account in routine clinical
ractice. Baseline variables had an overall chi-
quare of 16.15. The addition of variables obtained
t DSE increased the model’s power significantly.
he incremental value of SRs led to a further
ignificant increase in model power (Fig. 4). The
ame series of stepwise Cox models were under-
aken for those with and without ischemia and
hose with and without LVH (Fig. 5). The SRs was
ignificantly incremental to the model in each
ubgroup, with the exception of those without
schemia (p  0.19).
Fewer than one-third of patients were receiving
aintenance therapy with negative inotropic drugs,
hich were withdrawn before testing. There was no
ignificant difference in strain rate between those
aking and those not taking calcium channel block-
rs (2.42  0.66 s1 vs. 2.51  0.61 s1, p 
.62). Those taking chronic beta-blockade had
educed global SRs compared with those who were
ot (2.22  0.53 s1 vs. 2.61  0.63 s1, p 
.05), possibly influenced by the significant increase
n the number of individuals with ischemia in this
roup compared with those not taking beta-
lockers (51.4% vs. 17.2%, p  0.01).
H and Myocardial Ischemia
Baseline and DSE Obtained
lue HR 95% CI p Value
01 SRs 3.83 1.60–9.15 0.05
Resting
heart rate
2.29 1.34–3.94 0.01
SRs 4.98 1.75–14.16 0.01
Peak SBP 0.30 0.10–0.83 0.05
SRs 11.73 2.13–64.45 0.01A
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799I S C U S S I O N
he association of myocardial deformation with
tress and outcome might arise from not only
schemia but also LV hypertrophy, fibrosis, and
nfarction. In this study, although 5-year mortality
as associated with ischemia, LVH, and their
ombination, myocardial deformation had an asso-
iation with outcome that was independent of each.
n groups divided according to the presence or
bsence of ischemia or LVH, SRs was the only
ommon variable associated with mortality across
he 4 groups and the strongest correlate in 3 groups
Table 3). These data suggest a contribution of
yocardial properties to outcome.
The measurement of SRs is important, because
his is a marker of regional contractile function (11),
hich is preferable to strain as a marker of myocar-
ial function, especially during stress (6). Strain rate
as the strongest predictor of mortality, indepen-
ent of LVH and myocardial ischemia.
Increased LVMI was identified in 37% of our
opulation. Left ventricular hypertrophy has many
eleterious effects on myocardium, including de-
reased myocardial perfusion reserve and myocar-
ial efficiency (12). Coronary microcirculatory dys-
unction is present in LVH with raised RWT, with
he subendocardium preferentially affected (13).
The association between LVH and SRs during
SE has not been previously described; our finding
f reduced SRs in association with LVH clearly has
mplications for the use of this quantitative param-
ter as an adjunct to the interpretation of DSE.
here is a paucity of published data concerning
yocardial deformation and LVH. Our study has
nvestigated the ability of these techniques to detect
ubclinical myocardial change in a clinical popula-
Table 4. Predictors of All-Cause Mortality From LV Geometric P
Baseline
HR 95%
Normal geometry (n  76)
Concentric remodeling (n  64) Diabetes 6.31 1.39–2
Eccentric LVH (n  23)
Concentric LVH (n  60)
Normal RWT (n  99)
Raised RWT (n  124) Diabetes 2.90 1.28–6
SRs, peak SBP, and relative wall thickness (RWT) all analyzed per unit SD.
Abbreviations as in Tables 2 and 3.ion undergoing DSE.Not only LV mass but also LV geometry is a
eterminant of outcome. The increasing risk asso-
iated with progression from normal geometry to
oncentric remodeling and then concentric hyper-
rophy (1,14) was witnessed in our population.
ndividuals with concentric LVH have a worse
rognosis than those with eccentric LVH, irrespec-
ive of ischemic status (15). Resting SRs is signifi-
antly lower in those with concentric hypertrophy
ompared with those with normal geometry, inde-
endent of age, sex, and blood pressure (16). These
ndings suggest that SRs might reflect interstitial
hanges in those with concentric geometry.
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Figure 4. Prediction of Outcome for the Total Population
Model chi-square values are presented for a series of Cox models, t
with a table showing signiﬁcant predictors of outcome from each b
*p  0.01. DSE  variables obtained at dobutamine stress echocard
phy; HR  heart rate; LVH  left ventricular hypertrophy; SBP  sy
rns
Baseline and DSE Obtained
p Value HR 95% CI p Value
SRs 2.16 1.05–4.43 0.05
0.05 SRs 7.24 2.18–24.05 0.01
Peak SBP 0.12 0.02–0.69 0.05
SRs 1.76 1.18–2.63 0.01
0.01 SRs 2.31 1.66–3.23 0.01E & SRs
o p
<0.01
ogether
lock.
iogra-
stolicatte
CI
8.74
.56blood pressure; SRs  strain rate.
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800As previously described, the combination of
VH and ischemia demonstrated the additive in-
uence of these parameters on subsequent mortality
Fig. 3). Interestingly, the combination of these
athologies was reflected in abnormal SRs; the
rogression from normal geometry to LVH alone,
schemia alone, and then LVH and ischemia com-
ined was paralleled by a stepwise reduction of SRs.
his corresponded with the independent associa-
ion of SRs with mortality.
tudy limitations. Despite the consistent message
rom the study results, several limitations of the
tudy need to be considered. First, the use of
oppler-based strain rate permitted assessment of
ongitudinal rather than radial and circumferential
yocardial deformation. Second, the diagnosis of
schemia was based on the subjective assessment of
n experienced observer. This reflects the perfor-
ance of DSE in the clinical evaluation of our
atients—among whom a negative test for ischemia
72% of our population) would not normally result
n the patient proceeding to diagnostic coronary
ngiography. Moreover, individuals without isch-
mia diagnosed at DSE were indeed at low risk of
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Hazard Ratio p Hazard Ratio p Hazard Ratio p
DM 3.67 <0.01 7.64 <0.01
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Hazard Ratio p Hazard Ratio p Hazard Ratio p
LVH 3.64 <0.01
Resting HR 1.91 <0.05 1.65 <0.05
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Figure 5. Prediction of Outcome in Individuals With and Withou
Model chi-square values for a series of Cox models predicting outco
LVH, with signiﬁcant predictors of outcome from each model. DM oronary heart disease (men 3  2%, women 5  4%) (17). Third, although some patients were
aking medical therapy, we do not think this is a
ajor issue for several reasons, because 30% had
een taking either drug, and our standard protocol
s to withdraw beta-adrenoceptor and calcium
hannel antagonists on the day before the test.
inally, all-cause mortality rather than cardiac mor-
ality was examined, because the classification of
ardiac death is often problematic (18). However,
ecause the mean age of our population was 60 
2 years, we would expect most deaths to be cardiac
n origin.
O N C L U S I O N S
oth LVH and myocardial ischemia have a strong
ssociation with prognosis. However, the associations
f both LV geometry and deformation on outcome
uggest that other processes, including LV interstitial
hanges, might be associated with mortality.
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